首页> 美国卫生研究院文献>Journal of Diabetes Investigation >Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study

【2h】

Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study

机译：体重指数对日本2型糖尿病患者依普列净疗效和安全性的影响：依普列净治疗2型糖尿病患者特定药物使用结果调查的3个月中期结果的亚组分析：长期使用研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aims/IntroductionSpecified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use is an ongoing postmarketing study of ipragliflozin for long‐term use in Japanese patients with type 2 diabetes mellitus. A subgroup analysis of data from the study was carried out to investigate the impact of obesity on the efficacy and safety of ipragliflozin in this population.

机译：目的/介绍对2型糖尿病患者进行伊普列净治疗的特定药物使用结果调查：长期使用是一项正在进行的上市后伊普列净在日本2型糖尿病患者中长期使用的上市后研究。进行了一项研究数据的亚组分析，以研究肥胖对伊普利嗪在该人群中的疗效和安全性的影响。

著录项

期刊名称 Journal of Diabetes Investigation
作者
Kazuyuki Tobe; Hiroshi Maegawa; Hiromi Tabuchi; Ichiro Nakamura; Satoshi Uno;
展开▼
作者单位

展开▼
年(卷),期 2019(10),5
年度 2019
页码 1262–1271
总页数 10
原文格式 PDF
正文语种
中图分类基础医学;
关键词
Body mass index Ipragliflozin Postmarketing product surveillance;

机译：体重指数;伊普列净;上市后产品监测;

相似文献

外文文献
中文文献
专利

1. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type?2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type?2 Diabetic Patients: Long‐term Use study [J] . Kazuyuki Tobe, Hiroshi Maegawa, Hiromi Tabuchi, Journal of diabetes investigation. . 2019,第5期

机译：体重指数对日本2型糖尿病患者依普列净疗效和安全性的影响：依普列净治疗2型糖尿病患者指定药物使用结果调查的3个月中期结果的亚组分析：术语使用研究
2. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results) [J] . Hiromi Tabuchi, Hiroshi Maegawa, Kazuyuki Tobe, Endocrine journal . 2019,第1期

机译：依普列净对日本2型糖尿病患者肝功能的影响：STELLA-LONG TERM研究的亚组分析（3个月的中期结果）
3. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study [J] . Hiroshi Maegawa Expert opinion on pharmacotherapy . 2018,第1a6期

机译：IPRAGLIFLOZIN在老年人对非老年日本患者2型糖尿病的安全性和有效性：斯特拉长期研究的亚组分析
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Anti-diabetic treatment and cancer occurrence among patients with type II diabetes mellitus. [D] . Qiu, Hong. 2011

机译：II型糖尿病患者的抗糖尿病治疗和癌症发生。
6. A randomized double‐blind placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study [O] . A. Kashiwagi, H. Takahashi, H. Ishikawa, -1

机译：一项关于伊格列净治疗2型糖尿病和肾功能不全患者的长期疗效和安全性的随机双盲安慰剂对照研究：对患有肾功能不全的2型糖尿病患者进行长期ASP1941安全性评估的结果（LANTERN）研究
7. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results) [O] . Hiromi Tabuchi, Hiroshi Maegawa, Kazuyuki Tobe, 2019

机译：综外原对日本2型糖尿病患者肝功能的影响：斯特拉长期研究的亚组分析（3个月的中期结果）

Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study

摘要

著录项

相似文献

相关主题

期刊订阅